Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
A study reveals that shape-shifting immune cells, intermediate ILC2s, may contribute to severe asthma and resistance to ...
healthday on MSN6d
“Chameleon” Immune Cells Linked To Severe AsthmaA set of chameleon-like immune cells could be contributing to severe asthma in some patients.Intermediate group 2 i ...
If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...
Targeted biologic drugs have revolutionized the treatment of severe asthma driven by eosinophils, which are white blood cells linked to ILC2s, researchers noted in a recent study in the journal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback